Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 70 entries
Sorted by: Best Match Show Resources per page
Phenotyping of Live Human PBMC using CyTOF™ Mass Cytometry.

Bio-protocol

Leipold MD, Maecker HT.
PMID: 27390767
Bio Protoc. 2015;5(2). doi: 10.21769/bioprotoc.1382. Epub 2015 Jan 20.

Single-cell analysis has become an method of importance in immunology. Fluorescence flow cytometry has been a major player. However, due to issues such as autofluorescence and emission spillover between different fluorophores, alternative techniques are being developed. In recent years,...

Cite
Leipold MD, Maecker HT. Phenotyping of Live Human PBMC using CyTOF™ Mass Cytometry. Bio Protoc. 2015;5(2)doi: 10.21769/bioprotoc.1382.
Leipold, M. D., & Maecker, H. T. (2015). Phenotyping of Live Human PBMC using CyTOF™ Mass Cytometry. Bio-protocol, 5(2), . https://doi.org/10.21769/bioprotoc.1382
Leipold, Michael D, and Maecker, Holden T. "Phenotyping of Live Human PBMC using CyTOF™ Mass Cytometry." Bio-protocol vol. 5,2 (2015). doi: https://doi.org/10.21769/bioprotoc.1382
Leipold MD, Maecker HT. Phenotyping of Live Human PBMC using CyTOF™ Mass Cytometry. Bio Protoc. 2015;5(2). doi: 10.21769/bioprotoc.1382. Epub 2015 Jan 20. PMID: 27390767; PMCID: PMC4933512.
Copy Download .nbib Format: NLM
Cytokine fusion constructs as DNA vaccines against tumors.

Methods in molecular medicine

Maecker HT, Syrengelas A, Levy R.
PMID: 21374323
Methods Mol Med. 2000;29:221-39. doi: 10.1385/1-59259-688-6:221.

Various studies have used DNA vaccination as a method of immunizing against tumors (1-12). As with any tumor vaccine, one challenge is to find a truly tumor-specific antigen (13,14). The majority of immunologically targeted tumor antigens are also expressed...

Cite
Maecker HT, Syrengelas A, Levy R. Cytokine fusion constructs as DNA vaccines against tumors. Methods Mol Med. 2000;29:221-39doi: 10.1385/1-59259-688-6:221.
Maecker, H. T., Syrengelas, A., & Levy, R. (2000). Cytokine fusion constructs as DNA vaccines against tumors. Methods in molecular medicine, 29221-39. https://doi.org/10.1385/1-59259-688-6:221
Maecker, H T, et al. "Cytokine fusion constructs as DNA vaccines against tumors." Methods in molecular medicine vol. 29 (2000): 221-39. doi: https://doi.org/10.1385/1-59259-688-6:221
Maecker HT, Syrengelas A, Levy R. Cytokine fusion constructs as DNA vaccines against tumors. Methods Mol Med. 2000;29:221-39. doi: 10.1385/1-59259-688-6:221. PMID: 21374323.
Copy Download .nbib Format: NLM
Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.

Cell reports. Medicine

Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, Rowley J, Gotlib J, Zehnder J, Krishnan A.
PMID: 34755136
Cell Rep Med. 2021 Oct 19;2(10):100425. doi: 10.1016/j.xcrm.2021.100425. eCollection 2021 Oct 19.

Predicting disease progression remains a particularly challenging endeavor in chronic degenerative disorders and cancer, thus limiting early detection, risk stratification, and preventive interventions. Here, profiling the three chronic subtypes of myeloproliferative neoplasms (MPNs), we identify the blood platelet transcriptome...

Cite
Shen Z, Du W, Perkins C, et al. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Rep Med. 2021;2(10):100425doi: 10.1016/j.xcrm.2021.100425.
Shen, Z., Du, W., Perkins, C., Fechter, L., Natu, V., Maecker, H., Rowley, J., Gotlib, J., Zehnder, J., & Krishnan, A. (2021). Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell reports. Medicine, 2(10), 100425. https://doi.org/10.1016/j.xcrm.2021.100425
Shen, Zhu, et al. "Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms." Cell reports. Medicine vol. 2,10 (2021): 100425. doi: https://doi.org/10.1016/j.xcrm.2021.100425
Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, Rowley J, Gotlib J, Zehnder J, Krishnan A. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Rep Med. 2021 Oct 19;2(10):100425. doi: 10.1016/j.xcrm.2021.100425. eCollection 2021 Oct 19. PMID: 34755136; PMCID: PMC8561315.
Copy Download .nbib Format: NLM
Inflammatory cytokines and callosal white matter microstructure in adolescents.

Brain, behavior, and immunity

Ho TC, Kulla A, Teresi GI, Sisk LM, Rosenberg-Hasson Y, Maecker HT, Gotlib IH.
PMID: 34896593
Brain Behav Immun. 2022 Feb;100:321-331. doi: 10.1016/j.bbi.2021.12.003. Epub 2021 Dec 09.

Adolescent depression is characterized by heightened inflammation and altered connectivity of fronto-cingulate-limbic tracts, including the genu of the corpus callosum (CCG) and the uncinate fasciculus (UF). No studies, however, have yet examined the association between inflammation, measured by peripheral...

Cite
Ho TC, Kulla A, Teresi GI, et al. Inflammatory cytokines and callosal white matter microstructure in adolescents. Brain Behav Immun. 2021;100:321-331doi: 10.1016/j.bbi.2021.12.003.
Ho, T. C., Kulla, A., Teresi, G. I., Sisk, L. M., Rosenberg-Hasson, Y., Maecker, H. T., & Gotlib, I. H. (2022). Inflammatory cytokines and callosal white matter microstructure in adolescents. Brain, behavior, and immunity, 100321-331. https://doi.org/10.1016/j.bbi.2021.12.003
Ho, Tiffany C, et al. "Inflammatory cytokines and callosal white matter microstructure in adolescents." Brain, behavior, and immunity vol. 100 (2022): 321-331. doi: https://doi.org/10.1016/j.bbi.2021.12.003
Ho TC, Kulla A, Teresi GI, Sisk LM, Rosenberg-Hasson Y, Maecker HT, Gotlib IH. Inflammatory cytokines and callosal white matter microstructure in adolescents. Brain Behav Immun. 2022 Feb;100:321-331. doi: 10.1016/j.bbi.2021.12.003. Epub 2021 Dec 09. PMID: 34896593.
Copy Download .nbib Format: NLM
Insulin Growth Factor Phenotypes in Heart Failure with Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study: IGF axis in HFpEF.

Journal of cardiac failure

Haddad F, Ataam JA, Amsallem M, Cauwenberghs N, Kuznetsova T, Rosenberg-Hasson Y, Zamanian RT, Karakikes I, Horne BD, Muhlestein JB, Kwee L, Shah S, Maecker H, Knight S, Knowlton K.
PMID: 34979242
J Card Fail. 2021 Dec 31; doi: 10.1016/j.cardfail.2021.12.012. Epub 2021 Dec 31.

BACKGROUND: The insulin like growth factor (IGF) axis emerged as an important pathway in heart failure with preserved ejection (HFpEF). We aimed to identify IGF phenotypes associated with HFpEF in the context high-dimensional proteomic profiling.METHODS: From the Intermountain INSPIRE...

Cite
Haddad F, Ataam JA, Amsallem M, et al. Insulin Growth Factor Phenotypes in Heart Failure with Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study: IGF axis in HFpEF. J Card Fail. 2021;doi: 10.1016/j.cardfail.2021.12.012.
Haddad, F., Ataam, J. A., Amsallem, M., Cauwenberghs, N., Kuznetsova, T., Rosenberg-Hasson, Y., Zamanian, R. T., Karakikes, I., Horne, B. D., Muhlestein, J. B., Kwee, L., Shah, S., Maecker, H., Knight, S., & Knowlton, K. (2021). Insulin Growth Factor Phenotypes in Heart Failure with Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study: IGF axis in HFpEF. Journal of cardiac failure, . https://doi.org/10.1016/j.cardfail.2021.12.012
Haddad, Francois, et al. "Insulin Growth Factor Phenotypes in Heart Failure with Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study: IGF axis in HFpEF." Journal of cardiac failure vol. (2021). doi: https://doi.org/10.1016/j.cardfail.2021.12.012
Haddad F, Ataam JA, Amsallem M, Cauwenberghs N, Kuznetsova T, Rosenberg-Hasson Y, Zamanian RT, Karakikes I, Horne BD, Muhlestein JB, Kwee L, Shah S, Maecker H, Knight S, Knowlton K. Insulin Growth Factor Phenotypes in Heart Failure with Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study: IGF axis in HFpEF. J Card Fail. 2021 Dec 31; doi: 10.1016/j.cardfail.2021.12.012. Epub 2021 Dec 31. PMID: 34979242.
Copy Download .nbib Format: NLM
Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia.

Blood

Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda L, McDonald T, Lacayo NJ, Sakamoto KM, Carroll M, Tasian SK, Marcucci G, Yu J, Caligiuri MA, Maecker HT, Swaminathan S.
PMID: 34077953
Blood. 2021 Oct 21;138(16):1465-1480. doi: 10.1182/blood.2020009871.

B- and T-cell acute lymphoblastic leukemia (B/T-ALL) may be refractory or recur after therapy by suppressing host anticancer immune surveillance mediated specifically by natural killer (NK) cells. We delineated the phenotypic and functional defects in NK cells from high-risk...

Cite
Duault C, Kumar A, Taghi Khani A, et al. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021;138(16):1465-1480doi: 10.1182/blood.2020009871.
Duault, C., Kumar, A., Taghi Khani, A., Lee, S. J., Yang, L., Huang, M., Hurtz, C., Manning, B., Ghoda, L., McDonald, T., Lacayo, N. J., Sakamoto, K. M., Carroll, M., Tasian, S. K., Marcucci, G., Yu, J., Caligiuri, M. A., Maecker, H. T., & Swaminathan, S. (2021). Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood, 138(16), 1465-1480. https://doi.org/10.1182/blood.2020009871
Duault, Caroline, et al. "Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia." Blood vol. 138,16 (2021): 1465-1480. doi: https://doi.org/10.1182/blood.2020009871
Duault C, Kumar A, Taghi Khani A, Lee SJ, Yang L, Huang M, Hurtz C, Manning B, Ghoda L, McDonald T, Lacayo NJ, Sakamoto KM, Carroll M, Tasian SK, Marcucci G, Yu J, Caligiuri MA, Maecker HT, Swaminathan S. Activated natural killer cells predict poor clinical prognosis in high-risk B- and T-cell acute lymphoblastic leukemia. Blood. 2021 Oct 21;138(16):1465-1480. doi: 10.1182/blood.2020009871. PMID: 34077953; PMCID: PMC8532198.
Copy Download .nbib Format: NLM
Does the Implementation of the PRO-IMPLANT Foundation Treatment Algorithm Improve the Outcome of Chronic Periprosthetic Knee Infections? Mid-Term Results of a Prospective Study.

Zeitschrift fur Orthopadie und Unfallchirurgie

Hanusrichter Y, Frieler S, Gessmann J, Schulte M, Krejczy M, Schildhauer T, Baecker H.
PMID: 34753193
Z Orthop Unfall. 2021 Nov 09; doi: 10.1055/a-1562-2874. Epub 2021 Nov 09.

BACKGROUND: Several treatment options for chronic periprosthetic joint infections have been published in the current literature, with an on-going discussion to determine effective management algorithms.OBJECTIVES: To compare outcomes of the two-stage exchange procedure in revision TKA prior to and...

Cite
Hanusrichter Y, Frieler S, Gessmann J, et al. Verbessert die Implementierung des PRO-IMPLANT Foundation Behandlungsalgorithmus die Therapie chronischer periprothetischer Knieprotheseninfektionen? Ergebnisse einer prospektiven Studie. Does the Implementation of the PRO-IMPLANT Foundation Treatment Algorithm Improve the Outcome of Chronic Periprosthetic Knee Infections? Mid-Term Results of a Prospective Study. Z Orthop Unfall. 2021;doi: 10.1055/a-1562-2874.
Hanusrichter, Y., Frieler, S., Gessmann, J., Schulte, M., Krejczy, M., Schildhauer, T., & Baecker, H. (2021). Verbessert die Implementierung des PRO-IMPLANT Foundation Behandlungsalgorithmus die Therapie chronischer periprothetischer Knieprotheseninfektionen? Ergebnisse einer prospektiven Studie. Does the Implementation of the PRO-IMPLANT Foundation Treatment Algorithm Improve the Outcome of Chronic Periprosthetic Knee Infections? Mid-Term Results of a Prospective Study. Zeitschrift fur Orthopadie und Unfallchirurgie, . https://doi.org/10.1055/a-1562-2874
Hanusrichter, Yannik, et al. "Verbessert die Implementierung des PRO-IMPLANT Foundation Behandlungsalgorithmus die Therapie chronischer periprothetischer Knieprotheseninfektionen? Ergebnisse einer prospektiven Studie." Does the Implementation of the PRO-IMPLANT Foundation Treatment Algorithm Improve the Outcome of Chronic Periprosthetic Knee Infections? Mid-Term Results of a Prospective Study. Zeitschrift fur Orthopadie und Unfallchirurgie vol. (2021). doi: https://doi.org/10.1055/a-1562-2874
Hanusrichter Y, Frieler S, Gessmann J, Schulte M, Krejczy M, Schildhauer T, Baecker H. Verbessert die Implementierung des PRO-IMPLANT Foundation Behandlungsalgorithmus die Therapie chronischer periprothetischer Knieprotheseninfektionen? Ergebnisse einer prospektiven Studie. Does the Implementation of the PRO-IMPLANT Foundation Treatment Algorithm Improve the Outcome of Chronic Periprosthetic Knee Infections? Mid-Term Results of a Prospective Study. Z Orthop Unfall. 2021 Nov 09; doi: 10.1055/a-1562-2874. Epub 2021 Nov 09. German. PMID: 34753193.
Copy Download .nbib Format: NLM
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal for immunotherapy of cancer

Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D'Amico L, Lacroix A, Kaiser JC, Morre M, Grégoire A, Cheever M, Yu EY, Fong L.
PMID: 34452927
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002903.

BACKGROUND: Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytokine that enhances both B and T cell development and...

Cite
Pachynski RK, Morishima C, Szmulewitz R, et al. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021;9(8)doi: 10.1136/jitc-2021-002903.
Pachynski, R. K., Morishima, C., Szmulewitz, R., Harshman, L., Appleman, L., Monk, P., Bitting, R. L., Kucuk, O., Millard, F., Seigne, J. D., Fling, S. P., Maecker, H. T., Duault, C., Ramchurren, N., Hess, B., D'Amico, L., Lacroix, A., Kaiser, J. C., Morre, M., Grégoire, A., Cheever, M., Yu, E. Y., & Fong, L. (2021). IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer, 9(8), . https://doi.org/10.1136/jitc-2021-002903
Pachynski, Russell K, et al. "IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)." Journal for immunotherapy of cancer vol. 9,8 (2021). doi: https://doi.org/10.1136/jitc-2021-002903
Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D'Amico L, Lacroix A, Kaiser JC, Morre M, Grégoire A, Cheever M, Yu EY, Fong L. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002903. PMID: 34452927; PMCID: PMC8404457.
Copy Download .nbib Format: NLM
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity.

Science translational medicine

Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BY, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT.
PMID: 35040666
Sci Transl Med. 2022 Jan 18;eabm7853. doi: 10.1126/scitranslmed.abm7853. Epub 2022 Jan 18.

A damaging inflammatory response is implicated in the pathogenesis of severe coronavirus disease 2019 (COVID-19), but mechanisms contributing to this response are unclear. In two prospective cohorts, early non-neutralizing, afucosylated IgG antibodies specific to severe acute respiratory syndrome coronavirus...

Cite
Chakraborty S, Gonzalez JC, Sievers BL, et al. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Sci Transl Med. 2022;eabm7853doi: 10.1126/scitranslmed.abm7853.
Chakraborty, S., Gonzalez, J. C., Sievers, B. L., Mallajosyula, V., Chakraborty, S., Dubey, M., Ashraf, U., Cheng, B. Y., Kathale, N., Tran, K. Q. T., Scallan, C., Sinnott, A., Cassidy, A., Chen, S. T., Gelbart, T., Gao, F., Golan, Y., Ji, X., Kim-Schulze, S., Prahl, M., Gaw, S. L., Gnjatic, S., Marron, T. U., Merad, M., Arunachalam, P. S., Boyd, S. D., Davis, M. M., Holubar, M., Khosla, C., Maecker, H. T., Maldonado, Y., Mellins, E. D., Nadeau, K. C., Pulendran, B., Singh, U., Subramanian, A., Utz, P. J., Sherwood, R., Zhang, S., Jagannathan, P., Tan, G. S., & Wang, T. T. (2022). Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science translational medicine, eabm7853. https://doi.org/10.1126/scitranslmed.abm7853
Chakraborty, Saborni, et al. "Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity." Science translational medicine vol. (2022): eabm7853. doi: https://doi.org/10.1126/scitranslmed.abm7853
Chakraborty S, Gonzalez JC, Sievers BL, Mallajosyula V, Chakraborty S, Dubey M, Ashraf U, Cheng BY, Kathale N, Tran KQT, Scallan C, Sinnott A, Cassidy A, Chen ST, Gelbart T, Gao F, Golan Y, Ji X, Kim-Schulze S, Prahl M, Gaw SL, Gnjatic S, Marron TU, Merad M, Arunachalam PS, Boyd SD, Davis MM, Holubar M, Khosla C, Maecker HT, Maldonado Y, Mellins ED, Nadeau KC, Pulendran B, Singh U, Subramanian A, Utz PJ, Sherwood R, Zhang S, Jagannathan P, Tan GS, Wang TT. Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Sci Transl Med. 2022 Jan 18;eabm7853. doi: 10.1126/scitranslmed.abm7853. Epub 2022 Jan 18. PMID: 35040666.
Copy Download .nbib Format: NLM
Dual-probe 1D hybrid fs/ps rotational CARS for simultaneous single-shot temperature, pressure, and O.

Optics letters

Escofet-Martin D, Ojo AO, Collins J, Mecker NT, Linne M, Peterson B.
PMID: 32870850
Opt Lett. 2020 Sep 01;45(17):4758-4761. doi: 10.1364/OL.400595.

We employ dual-probe one-dimensional (1D) femtosecond (fs)/picosecond (ps) hybrid rotational coherent anti-Stokes Raman spectroscopy (HRCARS) to investigate simultaneous temperature, pressure, and

Cite
Escofet-Martin D, Ojo AO, Collins J, et al. Dual-probe 1D hybrid fs/ps rotational CARS for simultaneous single-shot temperature, pressure, and O. Opt Lett. 2020;45(17):4758-4761doi: 10.1364/OL.400595.
Escofet-Martin, D., Ojo, A. O., Collins, J., Mecker, N. T., Linne, M., & Peterson, B. (2020). Dual-probe 1D hybrid fs/ps rotational CARS for simultaneous single-shot temperature, pressure, and O. Optics letters, 45(17), 4758-4761. https://doi.org/10.1364/OL.400595
Escofet-Martin, David, et al. "Dual-probe 1D hybrid fs/ps rotational CARS for simultaneous single-shot temperature, pressure, and O." Optics letters vol. 45,17 (2020): 4758-4761. doi: https://doi.org/10.1364/OL.400595
Escofet-Martin D, Ojo AO, Collins J, Mecker NT, Linne M, Peterson B. Dual-probe 1D hybrid fs/ps rotational CARS for simultaneous single-shot temperature, pressure, and O. Opt Lett. 2020 Sep 01;45(17):4758-4761. doi: 10.1364/OL.400595. PMID: 32870850.
Copy Download .nbib Format: NLM
Intracellular Cytokine Staining (ICS) on Human Lymphocytes or Peripheral Blood Mononuclear Cells (PBMCs).

Bio-protocol

Gupta S, Maecker H.
PMID: 34604458
Bio Protoc. 2015 Apr 05;5(5):e1442. doi: 10.21769/BioProtoc.1442. eCollection 2015 Apr 05.

Production of cytokines plays an important role in the immune response. Cytokines are involved in many different pathways including the induction of many anti-viral proteins by IFN gamma, the induction of T cell proliferation by IL-2 and the inhibition...

Cite
Gupta S, Maecker H. Intracellular Cytokine Staining (ICS) on Human Lymphocytes or Peripheral Blood Mononuclear Cells (PBMCs). Bio Protoc. 2015;5(5):e1442doi: 10.21769/BioProtoc.1442.
Gupta, S., & Maecker, H. (2015). Intracellular Cytokine Staining (ICS) on Human Lymphocytes or Peripheral Blood Mononuclear Cells (PBMCs). Bio-protocol, 5(5), e1442. https://doi.org/10.21769/BioProtoc.1442
Gupta, Sheena, and Maecker, Holden. "Intracellular Cytokine Staining (ICS) on Human Lymphocytes or Peripheral Blood Mononuclear Cells (PBMCs)." Bio-protocol vol. 5,5 (2015): e1442. doi: https://doi.org/10.21769/BioProtoc.1442
Gupta S, Maecker H. Intracellular Cytokine Staining (ICS) on Human Lymphocytes or Peripheral Blood Mononuclear Cells (PBMCs). Bio Protoc. 2015 Apr 05;5(5):e1442. doi: 10.21769/BioProtoc.1442. eCollection 2015 Apr 05. PMID: 34604458; PMCID: PMC8443452.
Copy Download .nbib Format: NLM
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).

Clinical cancer research : an official journal of the American Association for Cancer Research

Chen HX, Song M, Maecker HT, Gnjatic S, Patton D, Lee JJ, Adam SJ, Moravec R, Liu XS, Cerami E, Lindsay J, Tang M, Hodi FS, Wu CJ, Wistuba II, Al-Atrash G, Bernatchez C, Bendall SC, Hewitt SM, Sharon E, Streicher H, Enos RA, Bowman MD, Tatard-Leitman VM, Sanchez-Espiridion B, Ranasinghe S, Pichavant M, Del Valle DM, Yu J, Janssens S, Peterson-Klaus J, Rowe C, Bongers G, Jenq RR, Chang CC, Abrams JS, Mooney M, Doroshow JH, Harris LN, Thurin M.
PMID: 33419780
Clin Cancer Res. 2021 Sep 15;27(18):5038-5048. doi: 10.1158/1078-0432.CCR-20-3241. Epub 2021 Jan 08.

PURPOSE: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the...

Cite
Chen HX, Song M, Maecker HT, et al. Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021;27(18):5038-5048doi: 10.1158/1078-0432.CCR-20-3241.
Chen, H. X., Song, M., Maecker, H. T., Gnjatic, S., Patton, D., Lee, J. J., Adam, S. J., Moravec, R., Liu, X. S., Cerami, E., Lindsay, J., Tang, M., Hodi, F. S., Wu, C. J., Wistuba, I. I., Al-Atrash, G., Bernatchez, C., Bendall, S. C., Hewitt, S. M., Sharon, E., Streicher, H., Enos, R. A., Bowman, M. D., Tatard-Leitman, V. M., Sanchez-Espiridion, B., Ranasinghe, S., Pichavant, M., Del Valle, D. M., Yu, J., Janssens, S., Peterson-Klaus, J., Rowe, C., Bongers, G., Jenq, R. R., Chang, C. C., Abrams, J. S., Mooney, M., Doroshow, J. H., Harris, L. N., & Thurin, M. (2021). Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical cancer research : an official journal of the American Association for Cancer Research, 27(18), 5038-5048. https://doi.org/10.1158/1078-0432.CCR-20-3241
Chen, Helen X, et al. "Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,18 (2021): 5038-5048. doi: https://doi.org/10.1158/1078-0432.CCR-20-3241
Chen HX, Song M, Maecker HT, Gnjatic S, Patton D, Lee JJ, Adam SJ, Moravec R, Liu XS, Cerami E, Lindsay J, Tang M, Hodi FS, Wu CJ, Wistuba II, Al-Atrash G, Bernatchez C, Bendall SC, Hewitt SM, Sharon E, Streicher H, Enos RA, Bowman MD, Tatard-Leitman VM, Sanchez-Espiridion B, Ranasinghe S, Pichavant M, Del Valle DM, Yu J, Janssens S, Peterson-Klaus J, Rowe C, Bongers G, Jenq RR, Chang CC, Abrams JS, Mooney M, Doroshow JH, Harris LN, Thurin M. Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. 2021 Sep 15;27(18):5038-5048. doi: 10.1158/1078-0432.CCR-20-3241. Epub 2021 Jan 08. PMID: 33419780; PMCID: PMC8491462.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 70 entries